Abstract
A 54-year-old man diagnosed with type 2 diabetes and hyperthyroidism was prescribed propylthiouracil (PTU) after the patient developed hepatic dysfunction on thiamazole. At 50 mg/day of PTU, he was stable with thyroid-stimulating hormone receptor and thyrotropic antibody titers remaining stable. After four years of taking PTU, he was referred to the Department of Nephrology due to a rapid increase in his serum creatinine (Cr) level. He showed impaired renal function (Cr 2.26 mg/dL; estimated glomerular filtration rate (eGFR), 25 mL/min). In addition, urinary β2-microglobulin (β2 MG) was increased to 71,980 μg/L and was positive for myeloperoxidase (MPO)-anti-neutrophil cytoplasmic antibody (ANCA) (33.9 U/mL). Gallium scintigraphy demonstrated a remarkable accumulation in both kidneys. The patient was diagnosed with tubulointerstitial nephritis based on a renal biopsy, the results of which suggested that it might have been induced by PTU. He was treated with prednisolone (PSL) at 30 mg/day. As a result, within two weeks, Cr, eGFR, and urinary β2 MG levels were progressively improved to 1.72 mg/dL, 34 mL/min, and 22,020 μg/L, respectively. Therefore, we tapered off the PSL with a dose of 5 mg/day after approximately one year. There have been no exacerbated renal function parameters. Although there are many reports on patients developing MPO-ANCA-positive crescentic glomerulonephritis after the administration of PTU, we report on a relatively rare case in which interstitial nephritis occurred after the administration of PTU.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE. American Association of Clinical Endocrinologists. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457–69.
Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9:724–34.
Burch HB, Cooper DS. Management of graves disease: a review. JAMA. 2015;314:2544–54.
Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol. 2014;9:905–13.
Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J. 2015;8:343–5.
Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, Donker AJ, von dem Borne AE, Goldschmeding R. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet. 1993;342:651–2.
Linton AL, Richmond JM, Clark WF, Lindsay RM, Driedger AA, Lamki LM. Gallium67 scintigraphy in the diagnosis of acute renal disease. Clin Nephrol. 1985;24:84–7.
Honda H, Shibata T, Hara H, Ban Y, Sugisaki T. Antineutrophil cytoplasmic antibodies in patients with Graves’ disease: association of antimyeloperoxidase autoantibodies with propylthiouracil therapy. Mod Rheumatol. 2003;13:305–12.
Honda H. MPO-ANCA in patients with Graves’ disease; strong association with propylthiouracil (PTU) therapy. Sarcoidosis. 1996;13:280.
Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatol Oxf. 2008;47:1515–20.
Gunton JE, Stiel J, Caterson RJ, McElduff A. Clinical case seminar: anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab. 1999;84:13–6.
Nakabayashi K, Sumiishi A, Sano K, Fujioka Y, Yamada A, Karube M, Koji H, Arimura Y, Nagasawa T. Tubulointerstitial nephritis without glomerular lesions in three patients with myeloperoxidase-ANCA-associated vasculitis. Clin Exp Nephrol. 2009;13:605–13.
Son D, Kanda H, Yamaguchi A, Kawabata K, Kawakami T, Kubo K, Higashihara M, Shimizu J, Uozaki H, Kuramochi S, Misaki Y, Takeuchi F, Yamamoto K. Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis with diffuse tubulointerstitial nephritis. J Nephrol. 2009;22:417–20.
Joyce E, Glasner P, Ranganathan S, Swiatecka-Urban A. Tubulointerstitial nephritis: diagnosis, treatment, ad monitoring. Pediatr Nephrol. 2016. doi:10.1007/s00467-016-3394-5.
Perazella MA. Drug use and nephrotoxicity in the intensive care unit. Kidney Int. 2010;81:1172–8.
Dysseleer A, Buysschaert M, Fonck C, Van Ginder Deuren K, Jadoul M, Tennstedt D, Cosyns JP, Daumerie C. Acute interstitial nephritis and fatal Stevens-Johnson syndrome after propylthiouracil therapy. Thyroid. 2000;10:713–6.
Chen YX, Yu HJ, Ni LY, Zhang W, Hu YW, Ren H, Chen XN, Wang XL, Li X, Pan XX, Wang WM, Chen N. Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases. J Rheumatol. 2007;34:2451–6.
Acknowledgments
We would like to deeply thank the medical personnel in charge of treatment for the present patient.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest associated with this manuscript.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
About this article
Cite this article
Nishimura, S., Nakao, K., Takeda, M. et al. Antithyroid drug-associated MPO-ANCA-positive tubulointerstitial nephritis in a type 2 diabetes patient: a case report. CEN Case Rep 6, 22–28 (2017). https://doi.org/10.1007/s13730-016-0237-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-016-0237-y